Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Umang Swami

Showing results (71-80 of 170) with videos related to

Pageof 17
Sort By:
Journal of Geriatric Oncology|August 13, 2019
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patientsAndrew W Hahn, John Esther, Benjamin Haaland, et al.
JAMA Network Open|July 11, 2024
Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials: A Meta-AnalysisSanjay Goel, Abdissa Negassa, Mohammad H Ghalib, et al.
The Journal of Urology|October 20, 2020
Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial CarcinomaUmang Swami, Benjamin Haaland, Adam Kessel, et al.
Future Oncology (London, England)|July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United StatesUmang Swami, Agnes Hong, Brandon Diessner, et al.
Annals of Translational Medicine|July 19, 2021
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseaseSwetha Alexander, Umang Swami, Aneet Kaur, et al.
Gynecologic Oncology|July 24, 2013
Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010June Y Hou, Santiago Aparo, Mohammad Ghalib, et al.
The Journal of Urology|February 15, 2023
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate CancerUmang Swami, Agnes Hong, Nader N El-Chaar, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
A Phase 2 Trial of Radium<sup>223</sup> and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR StudyJonathan Tward, Shane Lloyd, Skyler Johnson, et al.
The Oncologist|March 7, 2024
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, et al.
Cancers|July 29, 2023
Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0Georges Gebrael, Kamal Kant Sahu, Beverly Chigarira, et al.
Pageof 17

Showing results (71-80 of 170) with videos related to

Sort By:
Pageof 17
Journal of Geriatric Oncology|August 13, 2019
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patientsAndrew W Hahn, John Esther, Benjamin Haaland, et al.
JAMA Network Open|July 11, 2024
Outcomes Among Racial and Ethnic Minority Patients With Advanced Cancers in Phase 1 Trials: A Meta-AnalysisSanjay Goel, Abdissa Negassa, Mohammad H Ghalib, et al.
The Journal of Urology|October 20, 2020
Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial CarcinomaUmang Swami, Benjamin Haaland, Adam Kessel, et al.
Future Oncology (London, England)|July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United StatesUmang Swami, Agnes Hong, Brandon Diessner, et al.
Annals of Translational Medicine|July 19, 2021
Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseaseSwetha Alexander, Umang Swami, Aneet Kaur, et al.
Gynecologic Oncology|July 24, 2013
Clinical outcome and prognostic markers for patients with gynecologic malignancies in phase 1 clinical trials: a single institution experience from 1999 to 2010June Y Hou, Santiago Aparo, Mohammad Ghalib, et al.
The Journal of Urology|February 15, 2023
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate CancerUmang Swami, Agnes Hong, Nader N El-Chaar, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2025
A Phase 2 Trial of Radium<sup>223</sup> and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR StudyJonathan Tward, Shane Lloyd, Skyler Johnson, et al.
The Oncologist|March 7, 2024
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)Kamal Kant Sahu, Haoran Li, Vinay Mathew Thomas, et al.
Cancers|July 29, 2023
Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0Georges Gebrael, Kamal Kant Sahu, Beverly Chigarira, et al.
Pageof 17